The ARHGAP5 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human non-small cell lung cancer line, designed to eliminate functional expression of the ARHGAP5 gene. This loss-of-function model provides a heterogeneous pool of cells with diverse gene-disruption events, enabling robust analysis of ARHGAP5 (p190-B RhoGAP) function without clonal selection artifacts. The polyclonal format is ideal for studies requiring a broad representation of knockout genotypes, faithfully preserving the parental line’s key oncogenic mutations while specifically ablating ARHGAP5-dependent activities.
The A-549 host cell line is an epithelial model widely used in lung adenocarcinoma research, characterized by well-defined driver mutations in KRAS and STK11 (LKB1). These genetic alterations recapitulate aggressive tumor phenotypes, including enhanced proliferative signaling and metabolic reprogramming. The ARHGAP5 knockout in this background offers a unique platform to investigate how Rho GTPase regulation intersects with oncogenic pathways in non-small cell lung cancer, particularly in processes governing metastatic dissemination and cytoskeletal reorganization.
ARHGAP5 encodes the p190-B Rho GTPase-activating protein, a critical negative regulator of Rho family GTPases. Mechanistically, ARHGAP5 is recruited to focal adhesions upon integrin engagement, where it is phosphorylated by Src kinase and focal adhesion kinase (FAK). Activated ARHGAP5 stimulates GTP hydrolysis on RhoA and Rac1, thereby inactivating these GTPases and promoting actin filament disassembly, focal adhesion turnover, and modulation of cell adhesion and migration. The protein interacts with key focal adhesion components, including p120 RasGAP, paxillin, and vinculin, and functions within a signaling axis comprising integrins, FAK, Src, RhoA, Rac1, and the actin cytoskeleton.
Disruption of ARHGAP5 in A-549 cells provides a powerful tool to dissect the specific contribution of p190-B RhoGAP to lung adenocarcinoma malignancy. Given the prominence of KRAS-driven signaling and STK11 loss in this line, the knockout model enables detailed interrogation of how integrin-mediated Rho GTPase regulation influences cancer cell migration, invasion, and metastatic potential. By uncoupling ARHGAP5 from its downstream effectors, researchers can assess compensatory mechanisms involving other RhoGAP family members and delineate the precise roles of Src/FAK-dependent phosphorylation in controlling actin dynamics within a tumor-relevant genetic context.
This knockout product supports a range of downstream applications central to cancer cell biology and signal transduction research. Investigators can perform Western blotting to monitor RhoA and Rac1 activity levels, immunofluorescence to visualize actin cytoskeletal changes, and Boyden chamber assays to quantify migratory and invasive behavior. Additionally, co-immunoprecipitation experiments enable analysis of ARHGAP5-containing protein complexes, while phospho-signaling studies, such as phospho-Src immunoblotting, facilitate examination of upstream regulatory pathways. For further technical details or to inquire about custom options, please contact Ascent Research.
